Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17420715 | 0.85 | PDE2A (0.44) | PDE2APIM1EPHX2FFAR4FFAR1 | |
| SCHEMBL30628215 | 0.85 | PDE2A (0.44) | PDE2APIM1EPHX2FFAR4FFAR1 | |
| SCHEMBL30087715 | 0.83 | PIM1 (0.41) | PDE2APIM1EPHX2FFAR4EPHX1 | |
| SCHEMBL30087619 | 0.81 | PARP10 (0.46) | GAAKMT2A | |
| SCHEMBL17420469 | 0.78 | POLB (0.46) | PDE2AFFAR4FFAR1 | |
| SCHEMBL14155817 | 0.78 | PDE2A (0.45) | PDE2AKDM4EGAAGPR3 | |
| SCHEMBL29177399 | 0.77 | EPHX2 (0.45) | PDE2APIM1EPHX2FFAR4FFAR1 | |
| SCHEMBL22092981 | 0.77 | DGAT1 (0.51) | PIM1EPHX2FFAR4FFAR1KDM4E | |
| SCHEMBL30087624 | 0.75 | EPHX2 (0.43) | PDE2AEPHX2FFAR4GPR3KCNN4 | |
| SCHEMBL28958691 | 0.74 | EPHX2 (0.53) | PDE2APIM1EPHX2KMT2AKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320192-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20230242504-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | DEUTERX LLC (US) | 2023-08-03 | — | — | US | disclosed |
| US-11535603-B1 | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same | DEUTERX, LLC (US) | 2022-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242504-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | EGLN3, HPGDS, EGLN2 | PDE2A 630/4885PIM1 2626/4885EPHX2 1251/4885 |
| US-20250320192-A1 | DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | EGLN3, HPGDS, EGLN2 | PDE2A 630/4885PIM1 2626/4885EPHX2 1251/4885 |
| US-11535603-B1 | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same | EGLN3, HPGDS, EGLN2 | PDE2A 630/4885PIM1 2626/4885EPHX2 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.